Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- PMID: 22236695
- PMCID: PMC3319479
- DOI: 10.1016/j.coi.2011.12.009
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Abstract
Genetic alterations and epigenetic dysregulation in cancer cells create a vast array of neoepitopes potentially recognizable by the immune system. Immune checkpoint blockade has the capacity to enhance and sustain endogenous immunity against non-mutated tumor-associated antigens as well as uniquely mutant antigens, establishing durable tumor control. Recent evidence from preclinical models highlights the pivotal role of the Programmed Death-1 (PD-1) T cell co-receptor and its ligands, B7-H1/PD-L1 and B7-DC/PD-L2, in maintaining an immunosuppressive tumor microenvironment. Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063. Clin Cancer Res. 2013. PMID: 23460533 Free PMC article.
-
Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs.Pathol Oncol Res. 2020 Apr;26(2):651-663. doi: 10.1007/s12253-019-00735-9. Epub 2019 Nov 20. Pathol Oncol Res. 2020. PMID: 31748880 Review.
-
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.J Cell Physiol. 2019 Feb;234(2):1313-1325. doi: 10.1002/jcp.27172. Epub 2018 Sep 7. J Cell Physiol. 2019. PMID: 30191996 Review.
-
Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.Int Immunopharmacol. 2020 Jul;84:106584. doi: 10.1016/j.intimp.2020.106584. Epub 2020 May 15. Int Immunopharmacol. 2020. PMID: 32422527
-
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19. Hum Vaccin Immunother. 2019. PMID: 30888929 Free PMC article. Review.
Cited by
-
Inhibition of O-GlcNAc transferase activates type I interferon-dependent antitumor immunity by bridging cGAS-STING pathway.Elife. 2024 Oct 4;13:RP94849. doi: 10.7554/eLife.94849. Elife. 2024. PMID: 39365288 Free PMC article.
-
Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?Cells. 2024 Sep 16;13(18):1558. doi: 10.3390/cells13181558. Cells. 2024. PMID: 39329742 Free PMC article. Review.
-
I n situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases.Acta Pharm Sin B. 2024 Sep;14(9):4102-4117. doi: 10.1016/j.apsb.2024.06.003. Epub 2024 Jun 8. Acta Pharm Sin B. 2024. PMID: 39309485 Free PMC article.
-
A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer.Cancers (Basel). 2024 Sep 1;16(17):3052. doi: 10.3390/cancers16173052. Cancers (Basel). 2024. PMID: 39272910 Free PMC article.
-
Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC.Mol Cell Biochem. 2024 Sep 4. doi: 10.1007/s11010-024-05106-w. Online ahead of print. Mol Cell Biochem. 2024. PMID: 39231894
References
-
- Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548. - PubMed
-
-
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–3895. This seminal report describes the cloning of PD-1 (named for programmed death-1) from T cells undergoing activation induced cell death. Later studies demonstrated that PD-1 inhibits immunity through mechanisms other than apoptosis induction.
-
-
- Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813–824. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials